Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | CASP1 | P29466 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | CASP6 | P55212 | 1/20 | 0.41 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29626631 | 1.00 | LMNA (0.65) | LMNAL3MBTL1ALDH1A1CASP1KMT2A | |
| SCHEMBL10126622 | 0.85 | L3MBTL1 (0.63) | LMNAL3MBTL1ALDH1A1CASP1KMT2A | |
| SCHEMBL18739952 | 0.81 | BRD4 (0.50) | LMNAL3MBTL1ALDH1A1CASP1KMT2A | |
| SCHEMBL4977762 | 0.80 | L3MBTL1 (0.44) | LMNAL3MBTL1ALDH1A1CASP1KMT2A | |
| SCHEMBL9320070 | 0.80 | BRD4 (0.51) | LMNAL3MBTL1ALDH1A1CASP1GAA | |
| SCHEMBL17319217 | 0.80 | LMNA (0.69) | LMNAALDH1A1KMT2AGAATSHR | |
| SCHEMBL636186 | 0.79 | L3MBTL1 (0.55) | LMNAL3MBTL1ALDH1A1CASP1KMT2A | |
| SCHEMBL1805587 | 0.79 | ALOX5AP (0.41) | LMNAL3MBTL1ALDH1A1KMT2ACA2 | |
| SCHEMBL9322517 | 0.79 | KMT2A (0.56) | LMNAALDH1A1CASP1KMT2ACA2 | |
| SCHEMBL10635283 | 0.79 | RAPGEF4 (0.44) | LMNAL3MBTL1ALDH1A1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158355-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE MEDICINE (US) | 2024-05-16 | — | — | US | disclosed |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | NURIX THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| WO-2022159454-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BAYLOR COLLEGE OF MEDICINE (US) | 2022-07-28 | — | — | WO | disclosed |
| WO-2022032144-A1 | SUBSTRATE ADAPTOR INHIBITORS OF PRMT5 AND USES THEREOF | THE BROAD INSTITUTE, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| US-11198689-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-10752624-B2 | Kinase inhibitors | ORIGENIS GMBH (DE) | 2020-08-25 | — | — | US | disclosed |
| US-20200181130-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | RIGEL PHARMACEUTICALS, INC. (US) | 2020-06-11 | — | — | US | disclosed |
| US-10421752-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2019-09-24 | — | — | US | disclosed |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | ORIGENIS GMBH (DE) | 2018-10-25 | — | — | US | disclosed |
| US-7491732-B2 | Compositions and methods for inhibition of the JAK pathway | RIGEL PHARMACEUTICALS, INC. (US) | 2009-02-17 | — | — | US | disclosed |
| US-20090041786-A1 | e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | RIGEL PHARMACEUTICALS, INC. | 2009-02-12 | — | — | US | disclosed |
| US-20080306099-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
| US-20080306099-A1 | Prevent transplant rejection; autoimmune diseases | RIGEL PHARMACEUTICALS, INC. | 2008-12-11 | — | — | US | disclosed |
| EP-0372315-B1 | Reactive dyes based on copper formazane | BASF AG (DE) | 1994-01-26 | — | — | EP | disclosed |
| US-5245020-A | Reactive dyes with two or three nitrogen-containing haloheterocycles as reactive system | BASF AKTIENGESELLSCHAFT (DE) | 1993-09-14 | — | — | US | disclosed |
| US-5149789-A | Triazine dyes | BASF AKTIENGESELLSCHAFT (DE) | 1992-09-22 | — | — | US | disclosed |
| US-5041540-A | For dyeing or printing hydroxyl- or nitrogen-containing substrates | BASF AKTIENGESELLSCHAFT (DE) | 1991-08-20 | — | — | US | disclosed |
| EP-0391264-A1 | Reactive dyes with two or three halogen-N-heterocycles as reactive groups | BASF Aktiengesellschaft (DE) | 1990-10-10 | — | — | EP | disclosed |
| EP-0372315-A1 | Reactive dyes based on copper formazane | BASF Aktiengesellschaft (DE) | 1990-06-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158355-A1 | BET SUBFAMILY INHIBITORS AND METHODS USING SAME | BRDT, BRD3, BRD2 | LMNA 3572/4885L3MBTL1 1772/4885ALDH1A1 3781/4885 |
| US-20090041786-A1 | e.g. 5-Fluoro-N4-(3-hydroxyphenyl)-N2-[4-(N-methyl)aminosulfonyl-3-methoxyphenyl]-2,4-pyrimidinediamine; tyrosine (JAK) kinases inhibitor; interleukin and tumor necrosis factor ligand; transplant rejection; T-cell mediated autoimmune disease | JAK3, JAK1, JAK2 | LMNA 4714/4885L3MBTL1 3056/4885ALDH1A1 3574/4885 |
| US-11198689-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | LMNA 4271/4885L3MBTL1 3398/4885ALDH1A1 3966/4885 |
| US-11827628-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | LMNA 4271/4885L3MBTL1 3398/4885ALDH1A1 3966/4885 |
| US-20180305356-A1 | NOVEL KINASE INHIBITORS | LRRK2, MYLK2, MYLK | LMNA 3015/4885L3MBTL1 457/4885ALDH1A1 4333/4885 |
| US-20200181130-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF THE JAK PATHWAY | JAK3, JAK2, JAK1 | LMNA 4271/4885L3MBTL1 3398/4885ALDH1A1 3966/4885 |
| US-20080306099-A1 | Prevent transplant rejection; autoimmune diseases | JAK3, JAK1, JAK2 | LMNA 4846/4885L3MBTL1 2079/4885ALDH1A1 1981/4885 |
| US-20220387395-A1 | UREA, AMIDE, AND SUBSTITUTED HETEROARYL COMPOUNDS FOR CBL-B INHIBITION | CBLB, CBL, CBLC | LMNA 2705/4885L3MBTL1 370/4885ALDH1A1 4274/4885 |
| US-10752624-B2 | Kinase inhibitors | LRRK2, MYLK2, MYLK | LMNA 3115/4885L3MBTL1 485/4885ALDH1A1 4184/4885 |
| US-10421752-B2 | Compositions and methods for inhibition of the JAK pathway | JAK3, JAK2, JAK1 | LMNA 4271/4885L3MBTL1 3398/4885ALDH1A1 3966/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.